Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) Gross Margin: 2012-2025

Historic Gross Margin for Ptc Therapeutics (PTCT) over the last 14 years, with Sep 2025 value amounting to 92.52%.

  • Ptc Therapeutics' Gross Margin fell 197.00% to 92.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 96.83%, marking a year-over-year increase of 2548.00%. This contributed to the annual value of 92.89% for FY2024, which is 13.00% down from last year.
  • As of Q3 2025, Ptc Therapeutics' Gross Margin stood at 92.52%, which was down 1.17% from 93.62% recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Gross Margin peaked at 98.91% during Q1 2025, and registered a low of 90.52% during Q4 2023.
  • Moreover, its 3-year median value for Gross Margin was 93.60% (2023), whereas its average is 93.82%.
  • In the last 5 years, Ptc Therapeutics' Gross Margin slumped by 298bps in 2023 and then soared by 592bps in 2025.
  • Quarterly analysis of 5 years shows Ptc Therapeutics' Gross Margin stood at 94.36% in 2021, then plummeted by 86bps to 93.49% in 2022, then crashed by 298bps to 90.52% in 2023, then spiked by 184bps to 92.36% in 2024, then slumped by 197bps to 92.52% in 2025.
  • Its Gross Margin stands at 92.52% for Q3 2025, versus 93.62% for Q2 2025 and 98.91% for Q1 2025.